![]()
Rejoni, Inc., a commercial-stage women’s health company focused on uterine health, today announced that the first commercial procedure using the Juveena Hydrogel System has been performed by Serena H. Chen, MD, Founding Partner and Director of Advocacy, at CCRM Fertility of New Jersey in Livingston, N.J.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116137810/en/
Intrauterine adhesions (IUAs), the hallmark of Asherman’s syndrome, form when the uterine lining is injured, most often after hysteroscopic surgery or uterine curettage. They may cause infertility, recurrent pregnancy loss, menstrual changes, and serious obstetric complications such as abnormal placentation. Surgical removal of adhesions (adhesiolysis) is the standard of care, but adhesions frequently re-form after surgery. In moderate-to-severe disease, published recurrence rates are high, and many patients need repeat procedures before they can try to conceive.
“Performing the first Juveena case was a meaningful moment for our team and for our patients,” said Dr. Chen. “The Juveena hydrogel procedure was simple to complete at the end of the hysteroscopy and fit into our existing workflow. For women with intrauterine adhesions, the surgery is only half the battle. Adhesions that come back after adhesiolysis can mean more surgery, more delays, and lost time for patients who often do not have time to lose. Having an FDA-approved option backed by randomized controlled trial data is an important step toward reducing both how often adhesions recur and how severe they are when they do.”
“Dr. Chen and the CCRM Fertility of New Jersey team are leaders in reproductive medicine, and we are proud that they performed the first commercial Juveena case,” said John Nealon, President & CEO at Rejoni. “Clinicians have told us that recurrent adhesions are one of the most frustrating problems in reproductive surgery. Our goal is to give surgeons a purpose-built, evidence-based tool that helps protect the result of their work.”
About Juveena
The Juveena Hydrogel System is an FDA-approved, in situ-forming hydrogel system indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. The system uses a proprietary transcervical catheter to deliver two aqueous polymer solutions that rapidly form a soft, temporary hydrogel spacer. The hydrogel conforms to the uterine cavity and upper cervical canal, keeping the uterine walls apart while they heal. Juveena received FDA premarket approval in September 2026.
Indication and Important Safety Information
The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.
The Juveena Hydrogel System should not be used in patients with hemorrhage, active pelvic infection, sexually transmitted disease, or pregnancy, or in patients with known hypersensitivity or allergy to polyethylene glycol (PEG) or FD&C Blue #1 dye. Safety and effectiveness have not been established following hysteroscopic procedures other than adhesiolysis of moderate to severe intrauterine adhesions, or in patients undergoing thermal endometrial ablation. Patients should avoid pregnancy during the first complete menstrual cycle after treatment. Potential adverse reactions include discomfort, pain/cramping, infection, local inflammatory reaction, and allergic reaction. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician or licensed practitioner. For complete information, see the Instructions for Use at www.rejoni.com.
About Rejoni
Rejoni, Inc. is a privately held, commercial-stage medical device company based in Burlington, Massachusetts, developing gynecologic products based on its proprietary biomaterials. Founded in June 2020, Rejoni is the latest venture from serial entrepreneur Amar Sawhney, who also founded Confluent Surgical, Ocular Therapeutix, and Augmenix. More information about Rejoni can be found at www.rejoni.com.
About CCRM Fertility of New Jersey
CCRM Fertility of New Jersey, formerly the Institute for Reproductive Medicine and Science (IRMS), is part of CCRM Fertility, a global pioneer in fertility treatment, research, and science. From its main center in Livingston, N.J., and offices throughout the state, CCRM Fertility of New Jersey provides IVF, fertility testing, fertility preservation, egg freezing, third-party reproduction, and reproductive surgery. Founded by Dr. William Schoolcraft in 1987, CCRM Fertility leverages its own data and a dedicated team of in-house reproductive endocrinologists, embryologists, and geneticists to deliver industry-leading outcomes. More information can be found at www.ccrmivf.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116137810/en/
Media gallery